These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10423959)

  • 21. [Multi-drug-resistant tuberculosis in a Department of Infectious Diseases].
    Constant CA; Ferreira PB; Valadas E; Antunes F
    Acta Med Port; 2004; 17(2):157-66. PubMed ID: 15921647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of multi-drug resistant tuberculosis: practitioner's view point.
    Prasad R
    Indian J Tuberc; 2007 Jan; 54(1):3-11. PubMed ID: 17455417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of acquired MDR-TB and HIV co-infection.
    Deivanayagam CN; Rajasekaran S; Venkatesan R; Mahilmaran A; Ahmed PR; Annadurai S; Kumar S; Chandrasekar C; Ravichandran N; Pencillaiah R
    Indian J Chest Dis Allied Sci; 2002; 44(4):237-42. PubMed ID: 12437236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa.
    Andrews JR; Gandhi NR; Moodley P; Shah NS; Bohlken L; Moll AP; Pillay M; Friedland G; Sturm AW;
    J Infect Dis; 2008 Dec; 198(11):1582-9. PubMed ID: 18847372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cell immunity response in human pulmonary tuberculosis. Review].
    Rivas-Santiago B; Vieyra-Reyes P; Araujo Z
    Invest Clin; 2005 Dec; 46(4):391-412. PubMed ID: 16353546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased phosphorylation of STAT-1, STAT-4 and cytokine release in MDR-TB patients with primary resistance.
    Kim HJ; Chung DH; Kim MJ; Jang JH; Kim YW; Han SK; Shim YS; Yim JJ
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1071-6. PubMed ID: 18713507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunct immunotherapies for tuberculosis.
    Uhlin M; Andersson J; Zumla A; Maeurer M
    J Infect Dis; 2012 May; 205 Suppl 2():S325-34. PubMed ID: 22457298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs.
    Zumla A; Maeurer M
    J Infect Dis; 2012 May; 205 Suppl 2():S335-9. PubMed ID: 22448017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis].
    Luo Y; Lu S; Guo S
    Zhonghua Jie He He Hu Xi Za Zhi; 2000 Feb; 23(2):85-8. PubMed ID: 11778496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Reform of Japan's NTP and its technical perspectives].
    Mori T
    Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innate and adaptive immune responses to human Mycobacterium tuberculosis infection.
    Vankayalapati R; Barnes PF
    Tuberculosis (Edinb); 2009 Dec; 89 Suppl 1():S77-80. PubMed ID: 20006312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal models to evaluate the protective efficacy of tuberculosis vaccines.
    Griffin JF; Chinn DN; Rodgers CR; Mackintosh CG
    Tuberculosis (Edinb); 2001; 81(1-2):133-9. PubMed ID: 11463234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience.
    Thomas A; Ramachandran R; Rehaman F; Jaggarajamma K; Santha T; Selvakumar N; Krishnan N; Mohan NS; Sundaram V; Wares F; Narayanan PR
    Indian J Tuberc; 2007 Jul; 54(3):117-24. PubMed ID: 17886699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis.
    Teixeira L; Perkins MD; Johnson JL; Keller R; Palaci M; do Valle Dettoni V; Canedo Rocha LM; Debanne S; Talbot E; Dietze R
    Int J Tuberc Lung Dis; 2001 Apr; 5(4):321-8. PubMed ID: 11334250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa.
    Padayatchi N; Bamber S; Dawood H; Bobat R
    Pediatr Infect Dis J; 2006 Feb; 25(2):147-50. PubMed ID: 16462292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.